MA45574A - Procédés de traitement de lésions ou de pathologies liées à un dème du snc - Google Patents

Procédés de traitement de lésions ou de pathologies liées à un dème du snc

Info

Publication number
MA45574A
MA45574A MA045574A MA45574A MA45574A MA 45574 A MA45574 A MA 45574A MA 045574 A MA045574 A MA 045574A MA 45574 A MA45574 A MA 45574A MA 45574 A MA45574 A MA 45574A
Authority
MA
Morocco
Prior art keywords
ema
injuries
cns
procedures
treatment
Prior art date
Application number
MA045574A
Other languages
English (en)
Inventor
Sven Martin Jacobson
Original Assignee
Biogen Chesapeake Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Chesapeake Llc filed Critical Biogen Chesapeake Llc
Publication of MA45574A publication Critical patent/MA45574A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA045574A 2015-10-07 2016-10-07 Procédés de traitement de lésions ou de pathologies liées à un dème du snc MA45574A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07

Publications (1)

Publication Number Publication Date
MA45574A true MA45574A (fr) 2019-05-15

Family

ID=58488580

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045574A MA45574A (fr) 2015-10-07 2016-10-07 Procédés de traitement de lésions ou de pathologies liées à un dème du snc

Country Status (15)

Country Link
US (2) US20180280325A1 (fr)
EP (1) EP3359162B1 (fr)
JP (3) JP7349786B2 (fr)
KR (1) KR20180063296A (fr)
CN (2) CN115737816A (fr)
AU (2) AU2016335767B2 (fr)
BR (1) BR112018006925A2 (fr)
CA (1) CA3001321A1 (fr)
EA (1) EA201890893A1 (fr)
ES (1) ES2940669T3 (fr)
HK (1) HK1257542A1 (fr)
IL (1) IL258509B2 (fr)
MA (1) MA45574A (fr)
MX (1) MX2018004286A (fr)
WO (1) WO2017062765A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109512805B (zh) 2012-05-08 2021-12-31 埃罗米克斯公司 用于治疗水通道蛋白介导的疾病的化合物
JP6535338B2 (ja) 2013-11-06 2019-06-26 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規製剤
WO2020041905A1 (fr) * 2018-08-31 2020-03-05 The University Of British Columbia Procédés pour l'identification de composés adaptés au traitement de traumatismes du système nerveux central et utilisations de ces composés
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
WO2022012666A1 (fr) * 2020-07-17 2022-01-20 上海森辉医药有限公司 Dérivé de sulfonylurée et leurs utilisations médicales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
HUE051368T2 (hu) 2002-03-20 2021-03-01 Univ Maryland Nem szelektív kationcsatorna idegsejtekben és a csatornát blokkoló vegyületek az agyduzzanat kezelésére
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
WO2009002832A2 (fr) 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibiteurs de canaux ncca-atp pour thérapie
PT2868315T (pt) * 2007-12-04 2017-09-04 Remedy Pharmaceuticals Inc Formulações melhoradas e métodos para liofilização e liofilizados assim produzidos
CA3225438A1 (fr) 2010-07-19 2012-01-26 Remedy Pharmaceuticals, Inc. Procedes d'administration par voie intraveineuse de glyburide et autres medicaments

Also Published As

Publication number Publication date
BR112018006925A2 (pt) 2018-10-16
AU2022279369A1 (en) 2023-01-19
JP2018530564A (ja) 2018-10-18
EA201890893A1 (ru) 2018-09-28
CN115737816A (zh) 2023-03-07
JP7349786B2 (ja) 2023-09-25
CA3001321A1 (fr) 2017-04-13
ES2940669T3 (es) 2023-05-10
JP2023053274A (ja) 2023-04-12
US11951085B2 (en) 2024-04-09
AU2016335767A8 (en) 2018-06-28
CN108348534A (zh) 2018-07-31
KR20180063296A (ko) 2018-06-11
EP3359162A1 (fr) 2018-08-15
HK1257542A1 (zh) 2019-10-25
WO2017062765A1 (fr) 2017-04-13
EP3359162A4 (fr) 2019-08-28
IL258509B (en) 2022-12-01
AU2016335767B2 (en) 2022-10-06
AU2016335767A1 (en) 2018-05-24
JP2021073317A (ja) 2021-05-13
IL258509A (en) 2018-05-31
EP3359162B1 (fr) 2022-12-21
US20220125750A1 (en) 2022-04-28
MX2018004286A (es) 2018-08-09
US20180280325A1 (en) 2018-10-04
IL258509B2 (en) 2023-04-01

Similar Documents

Publication Publication Date Title
MA50056A (fr) Procédés de traitement de tumeur
ZA201706944B (en) Process for the purification of water
MA43872A (fr) Procédé de traitement d'une glomérulopathie à c3
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MA45574A (fr) Procédés de traitement de lésions ou de pathologies liées à un dème du snc
MA41449A (fr) Polythérapies pour le traitement de cancers
MA39748A (fr) Cenicriviroc pour le traitement de la fibrose
MA52906A (fr) Procédé de préparation d'amg 416
MA42999A (fr) Polythérapie pour le traitement de malignités
MA43040A (fr) Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
MA43106A (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
FR3027943B1 (fr) Detection d'une canalisation bloquee
MA41490A (fr) Procédé de prévention ou de traitement de la perte auditive
MA45973A (fr) Combinaisons d'inhibiteurs de btk pour le traitement du myélome multiple
DK3286260T3 (da) Polyolefinrør
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
MA51525A (fr) Traitement de minéraux
FR3038312B1 (fr) Procede de preparation de polyols
FR3039368B1 (fr) Procede de traitement cosmetique
MA42249A (fr) Traitement de carcinome de la ligne médiane nut
FR3036200B1 (fr) Methode de calibration pour equipements de traitement thermique
MA41961A (fr) Procédés de régénération d'adsorbants solides
MA42444A (fr) Traitement du prurit
MA47112A (fr) Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme